|Bid||9.07 x 900|
|Ask||9.57 x 900|
|Day's range||8.90 - 9.52|
|52-week range||8.90 - 31.55|
|Beta (5Y monthly)||0.15|
|PE ratio (TTM)||N/A|
|Earnings date||01 Nov 2023 - 06 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||32.75|
Early in the coronavirus pandemic, Vir Biotechnology's (NASDAQ: VIR) stock rose -- literally and figuratively -- as it joined the list of biotechs looking for vaccines and therapies for the disease. Vir's shares are down by 47% this year alone. This could be a buying opportunity for long-term investors, but only if Vir has enough growth fuel left in the tank.
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -19.83% and 71.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Regulatory and key pipeline updates from BridgeBio (BBIO) and argenx (ARGX) are in focus in the biotech sector.